<SEC-DOCUMENT>0001104659-25-004636.txt : 20250121
<SEC-HEADER>0001104659-25-004636.hdr.sgml : 20250121
<ACCEPTANCE-DATETIME>20250121060209
ACCESSION NUMBER:		0001104659-25-004636
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250121

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BELITE BIO, INC
		CENTRAL INDEX KEY:			0001889109
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93970
		FILM NUMBER:		25540243

	BUSINESS ADDRESS:	
		STREET 1:		12750 HIGH BLUFF DRIVE SUITE 475
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-246-6240

	MAIL ADDRESS:	
		STREET 1:		12750 HIGH BLUFF DRIVE SUITE 475
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lin Yu-Hsin
		CENTRAL INDEX KEY:			0001965964
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	MAIL ADDRESS:	
		STREET 1:		12750 HIGH BLUFF DRIVE, SUITE 475
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LIn Yu-Hsin
		DATE OF NAME CHANGE:	20230215
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Lin Yu%2DHsin -->
          <cik>0001965964</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Ordinary shares, par value US$0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001889109</issuerCik>
        <issuerName>BELITE BIO, INC</issuerName>
        <issuerCusip>07782B104</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>12750 High Bluff Drive Suite 475,</com:street1>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92130</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Yu-Hsin Lin</reportingPersonName>
      <citizenshipOrOrganization>C3</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>2287070.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2287070.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2287070.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>7.1</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Notes to row 9: Include (i) 394,774 Ordinary Shares directly held by Yu-Hsin Lin; (ii) 407,229 Ordinary Shares underlying share options granted to Yu-Hsin Lin that are vested or will be vested within 60 days of December 31, 2024; and (iii) 1,485,067 Ordinary Shares indirectly held by Yu-Hsin Lin through Lin Bioscience International Ltd., which is our principal shareholder and the wholly-owned subsidiary of our controlling shareholder Lin BioScience, Inc.(stock code: 6696.TW).

Notes to row 11: The percentage is calculated based upon an aggregate of (i) 31,826,549 Ordinary Shares outstanding as of December 31, 2024 as provided by the Issuer; and (ii) 407,229 Ordinary Shares underlying share options granted to Yu-Hsin Lin that are vested or will be vested within 60 days of December 31, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>BELITE BIO, INC</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>12750 High Bluff Drive Suite 475, San Diego, CA 92130, United States of America</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This Schedule 13G is filed on behalf of Yu-Hsin Lin ("Reporting Person")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The business address of the Reporting Person is 36F., No. 68, Sec. 5, Zhongxiao E. Rd., Xinyi Dist., Taipei City 110, Taiwan</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Yu-Hsin Lin is a citizen of Australia</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>2,287,070</amountBeneficiallyOwned>
        <classPercent>7.1</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>2,287,070</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>2,287,070</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Yu-Hsin Lin</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Yu-Hsin Lin</signature>
        <title>Yu-Hsin Lin,Chief Executive Officer and Chairman</title>
        <date>01/21/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
